Payment overview · 2025
General Payments
$974.51
61 reported records · 16 companies
Healthcare provider profile · identity verified
Nicholas Licari, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FLORENCE, SC · NPI 1558721779
Verified facts
What the public records show
CMS Open Payments records show Nicholas Licari, FNP received $974.51 in general payments during 2025 across 61 reported records.
Novo Nordisk Inc accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Linzess by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 385 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $238.19 | 24.4% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $216.82 | 22.2% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $144.97 | 14.9% | 9 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $60.39 | 6.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $59.09 | 6.1% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $49.91 | 5.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.52 | 4.6% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $25.11 | 2.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.38 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.17 | 2.1% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.82 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.01 | 1.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.66 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.21 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.61 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.65 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $942.24 | 60 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $203.19 | 14 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $92.62 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $84.95 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $84.35 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $77.63 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $71.89 | 4 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $60.39 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $59.09 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $56.72 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $52.35 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $52.35 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.91 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.52 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.52 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.09 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.17 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 45 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 106 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 140 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 385 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 143 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
106 | 36 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
143 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
206 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
140 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
385 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 609 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 471 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 460 | 128 |
| Fluticasone Propionate | Fluticasone Propionate | 410 | 133 |
| Ozempic | Semaglutide | 385 | 58 |
| Furosemide | Furosemide | 378 | 107 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 377 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 312 | 82 |
| Gabapentin | Gabapentin | 279 | 75 |
| Metformin Hcl Er | Metformin Hcl | 238 | 73 |
| Montelukast Sodium | Montelukast Sodium | 227 | 72 |
| Jardiance | Empagliflozin | 206 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 202 | 56 |
| Famotidine | Famotidine | 194 | 55 |
| Omeprazole | Omeprazole | 189 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 169 | 46 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 161 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 158 | 38 |
| Losartan Potassium | Losartan Potassium | 151 | 33 |
| Carvedilol | Carvedilol | 145 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 143 | 46 |
| Prednisone | Prednisone | 141 | 104 |
| Mounjaro | Tirzepatide | 140 | 30 |
| Ezetimibe | Ezetimibe | 139 | 36 |
| Potassium Chloride | Potassium Chloride | 139 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 136 | 66 |
| Lisinopril | Lisinopril | 134 | 37 |
| Tramadol Hcl | Tramadol Hcl | 130 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 114 | 37 |
| Allopurinol | Allopurinol | 110 | 33 |
| Spironolactone | Spironolactone | 110 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 33 |
| Nifedipine Er | Nifedipine | 109 | 27 |
| Linzess | Linaclotide | 106 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 30 |
| Pregabalin | Pregabalin | 98 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 27 |
| Trazodone Hcl | Trazodone Hcl | 90 | 24 |
| Eliquis | Apixaban | 84 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 19 |
| Meloxicam | Meloxicam | 78 | 50 |
| Bupropion Xl | Bupropion Hcl | 76 | 15 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 75 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 20 |
| Valsartan | Valsartan | 69 | 27 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 67 | 15 |
| Chlorthalidone | Chlorthalidone | 67 | 20 |
| Levetiracetam | Levetiracetam | 67 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 66 | suppressed |
| Mirtazapine | Mirtazapine | 65 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 63 | 27 |
| Metformin Hcl | Metformin Hcl | 60 | 13 |
| Meclizine Hcl | Meclizine Hcl | 59 | 15 |
| Sucralfate | Sucralfate | 57 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 52 |
| Buspirone Hcl | Buspirone Hcl | 55 | 12 |
| Topiramate | Topiramate | 53 | 16 |
| Farxiga | Dapagliflozin Propanediol | 51 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 50 | 13 |
| Alendronate Sodium | Alendronate Sodium | 49 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 48 | 44 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 45 | 12 |
| Kerendia | Finerenone | 45 | 11 |
| Colchicine | Colchicine | 44 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | 12 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 16 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 30 |
| Fluconazole | Fluconazole | 37 | 29 |
| Methylprednisolone | Methylprednisolone | 37 | 35 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 37 | 11 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 35 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | 11 |
| Donepezil Hcl | Donepezil Hcl | 32 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 25 |
| Ketoconazole | Ketoconazole | 30 | 17 |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Finasteride | Finasteride | 28 | 11 |
| Baclofen | Baclofen | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 11 |
| Roflumilast | Roflumilast | 27 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 17 |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Tradjenta | Linagliptin | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $974.51 · 61 records | Novo Nordisk Inc | AREXVY, Auvelity, CLOTTRIEVER BOLD CATHETER, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, GEMTESA, Kerendia, LINZESS, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, PENMENVY, QULIPTA, QUTENZA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error